Belvedere Trading’s Voyager Therapeutics VYGR Stock Holding History

Belvedere Trading’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,700	Closed	-$43.9K	–	1175
2023 Q1	$43.9K	Buy	+5,700	New	+$45.3K	﹤0.01%	604

Other funds holding VYGR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Belvedere Trading's VYGR Position: Q3 2022 in Review

Belvedere Trading sold out of Voyager Therapeutics (VYGR) in Q3 2022, closing a stake of 26,432 shares — an estimated $182K sold.

Belvedere Trading first reported a position in VYGR in Q3 2021 and held it in 4 quarters. The position peaked at $347K in Q1 2022. 69 funds tracked by Wall St. Rank hold VYGR as of Q3 2022.

Belvedere Trading reported no remaining Voyager Therapeutics position as of Q3 2022 after selling out during the quarter.
Belvedere Trading sold 26,432 Voyager Therapeutics shares in Q3 2022, an estimated $182K.
Belvedere Trading first reported a position in Voyager Therapeutics in Q3 2021 and held it in 4 quarters.
Belvedere Trading's Voyager Therapeutics position peaked at $347K in Q1 2022.
69 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2022.

Based on Belvedere Trading's 13F filing for Q3 2022, filed 26 Oct 2022.